NCT06724016 - Dose Escalation and Expansion Study of HM16390 in Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

215

Participants

Timeline

Start Date

December 11, 2024

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2030

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG

HM16390

HM16390 will be administered subcutaneously using syringes (35mg/mL) on Day 1 of every 3-week treatment cycle

Trial Locations (3)

NOT_YET_RECRUITING

Massachusetts General Hospital, Boston

ACTIVE_NOT_RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Samsung Medical Center, Seoul